Ботулинический нейротоксин и хроническая мигрень: хемоденервация мышечных волокон или модуляция ноцицептивной системы?

Обложка

Цитировать

Полный текст

Об авторах

А. Р. Артеменко

ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова»

Автор, ответственный за переписку.
Email: aartemenko@gmail.com
Россия

А. Л. Куренков

ФГБУ «Научный центр здоровья детей» РАМН

Email: fake@neicon.ru
Россия

С. С. Никитин

НИИ общей патологии и патофизиологии РАМН, Москва

Email: fake@neicon.ru
Россия

К. В. Беломестова

ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова»

Email: fake@neicon.ru
Россия

Список литературы

  1. Артеменко А.Р., Куренков А.Л. Ботулинический токсин: вчера, сегодня, завтра. Нервно-мышечные болезни 2013;2:6–18.
  2. Burgen A., Dickens F., Zatman L. J. The action of botulinum toxin on the neuromusculat junction. J Phisiol 1949;109:10–24.
  3. Aoki K.R., Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord 2011;17(Suppl 1):28–33.
  4. Wheeler A., Smith H.S. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology 2013;06:24–146.
  5. Jabbari B., Machado D. Treatment of Refractory Pain with Botulinum Toxins – An Evidence-Based Review. Pain Med 2011;12(11):1594–606.
  6. Aurora S.K., Dodick D.W., Turkel C.C. et al. PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30 (7):793–803.
  7. Blumenfeld A., Silberstein S.D., Dodick D.W. et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010;50(9):1406–18.
  8. Cady R.K., Schreiber C.P., Porter J.A. et al. A Multi-Center Double-Blind Pilot Comparison of OnabotulinumtoxinA and Topiramate for the Prophylactic Treatment of Chronic Migraine. Headache 2011;51(1):21–32.
  9. Diener H.C., Dodick D.W., Aurora S.K. et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30 (7):804–14.
  10. Dodick D.W., Turkel C.C., DeGryse R.E. et al. PREEMPT Chronic Migraine Study Group. Onabotulinum toxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50(6):921–36.
  11. Lipton R.B., Varon S.F., Grosberg B. et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011;77(15):1465–72.
  12. Silberstein S.D., Blumenfeld A.M., Cady R.K. et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013;15;331(1–2):48–56.
  13. Headache Classification Commitee of the International Headache Society. The Internetional Classification of Headache Disorders, 3rd edition (beta version), Cephalalgia 2013;33(9):629–808.
  14. Артеменко А.Р. Хроническая мигрень: клиника, патогенез, лечение. Дис. ... д-ра мед.наук. М., 2010. 205 с.
  15. Артеменко А.Р., Куренков А.Л. Хроническая мигрень. М.: ИД «АБВ-пресс», 2012. 488 с.
  16. Bigal M.E., Serrano D., Reed M., Lipton R.B. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71(8):559–66.
  17. Katsarava Z., Dzagnidze A., Kukava M. et al. Primary headache disorders in the Republic of Georgia: Prevalence and risk factors. Neurology 2009;73:1796–803.
  18. Natoli J.L., Manack A., Dean B. et al. Global prevalence of chronic migraine: а systematic review. Cephalalgia 2010;30:599–609.
  19. Reed M.L., Buse D.C., Manack A.N. et al. Prevalence of chronic migraine (CM), headache-related disability and sociodemographic factors in the US population: Results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2011;51:28 [abstr. P58].
  20. Артеменко А.Р., Куренков А.Л., Никитин С.С. Лечение хронической мигрени. Журн неврол и психиатр 2011;111(5):85–9.
  21. Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43(Suppl 1):9–15.
  22. Артеменко А.Р., Куренков А.Л. Дисфункция краниоцервикальных мышц при хронической мигрени. Нервно-мышечные болезни 2011;1:51–5.
  23. Cheshire W.P., Abashian S.W., Mann J.D. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994;59(1):65–9.
  24. Wheeler A.H., Goolkasian P., Gretz S.S. Botulinum toxin A for the treatment of chronic neck pain. Pain 2001;94(3):255–60.
  25. Criscuolo C.M. Interventional approaches to the management of myofascial pain syndrome. Curr Pain Headache Rep 2001;5(5):407–11.
  26. Gobel H., Heinze A., Kuhn K.H. et al. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2001;91:195–9.
  27. Wheeler A.H. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998;38(6):468–71.
  28. Filippi G.M., Errico P., Santarelli R. et al. Botulinum A toxin effect on rat jaw muscle spindles. Acta Otolaryngol 1993;113:400–4.
  29. Silberstein S.D. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacoter 2001;2:1649–54.
  30. Brin M.F., Fahn S., Moskowitz C. et al. Localized in ections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988;50:599–608.
  31. Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity and immunology. Muscle Nerve 1997;20:146–68.
  32. Smuts J.A., Schultz D., Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache 2004;44(8):801–5.
  33. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26(5):785–93.
  34. Cui M., Khanijou S., Rubino J., Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107(1–2):125–33.
  35. Dressler D., Saberi F.A., Barbosa E.R. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005;63:180–5.
  36. Durham P.L., Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache 2011;51(10):1573–7.
  37. Gazerani P., Staahl C., Drewes A.M., Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006;122(3):315–25.
  38. Gazerani P., Pedersen N.S., Staahl C. et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009;141(1–2):60–9.
  39. Purkiss J., Welch M., Doward S., Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000;59(11):1403–6.
  40. Welch M.J., Purkiss J.R., Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38(2):245–58.
  41. Артеменко А.Р., Орлова О.Р. Ботулинический токсин типа А: расширение возможностей терапии первичных головных болей. Врач 2007;5:40–3.
  42. Куренков А.Л., Артеменко А.Р., Никитин С.С., Орлова О.Р. Современные представления о механизмах действия ботулинического токсина типа А. Врач 2009;7:8–12.
  43. Cernuda-Morollón E., Larrosa D., Ramón C. et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013 [В печати].
  44. Aurora S.K., Winner P., Freeman M.C. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56- week PREEMPT clinical program. Headache 2011;51:1358–73.
  45. Drinovac V., Bach-Rojecky L., Matak I., Lacković Z. Involvement of μ-opioid receptors in antinociceptive action of botulinum toxin type A. Neuropharmacology 2013;70:331–7.
  46. Mathew N.T., Frishberg B.M., Gawel M. et al. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:293–307.
  47. Silberstein S.D., Stark S.R., Lucas S.M. et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005;80:1126–37.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Артеменко А.Р., Куренков А.Л., Никитин С.С., Беломестова К.В., 2013

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 85909 от  25.08.2023.